ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.

Gilchrist, Francis J; Bui, Stephanie; Gartner, Silvia; McColley, Susanna A; Tiddens, Harm; Ruiz, Gary; Stehling, Florian; Alani, Muhsen; Gurtovaya, Oksana; Bresnik, Mark; Watkins, Timothy R; Frankovic, Biliana; Skov, Marianne

Abstract

Antibiotic eradication therapies recommended for newly isolated Pseudomonas aeruginosa (Pa) in people with cystic fibrosis (pwCF) can be burdensome. ALPINE2 compared the efficacy and safety of a shortened 14-day course of aztreonam for inhalation solution (AZLI) with 28-day AZLI in paediatric pwCF. ALPINE2 (a double-blind, phase 3b study) included children aged 3 months to <18 years with CF and new-onset Pa infection. Participants were randomized to receive 75 mg AZLI three times daily for either 28 or 14 days followed by 14 days' matched placebo. The primary endpoint was rate of primary Pa eradication (no Pa detected during the 4 weeks post AZLI treatment). Non-inferiority was achieved if the lower 95% CI bound of the treatment difference between the two arms was above -20%. Secondary endpoints included assessments of Pa recurrence during 108 weeks of follow-up after primary eradication. Safety endpoints included treatment-emergent adverse events (TEAEs). In total, 149 participants were randomized (14-day AZLI, n = 74; 28-day AZLI, n = 75) and 142 (95.3%) completed treatment. Median age: 6.0 years (range: 0.3-17.0). Baseline characteristics were similar between treatment arms. Primary Pa eradication rates: 14-day AZLI, 55.9%; 28-day AZLI, 63.4%; treatment difference (CI), -8.0% (-24.6, 8.6%). Pa recurrence rates at follow-up end: 14-day AZLI, 54.1% (n = 20/37); 28-day AZLI, 41.9% (n = 18/43). TEAEs were similar between treatment arms. No new safety signals were observed. Non-inferiority of 14-day AZLI versus 28-day AZLI was not demonstrated. Both courses were well tolerated, further supporting AZLI short-term safety in paediatric and adolescent pwCF. GOV: NCT03219164. [Abstract copyright: Copyright © 2023. Published by Elsevier B.V.]

Citation

Gilchrist, F. J., Bui, S., Gartner, S., McColley, S. A., Tiddens, H., Ruiz, G., …Skov, M. (in press). ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis. Journal of Cystic Fibrosis, 23(1), 80-86. https://doi.org/10.1016/j.jcf.2023.06.008

• Journal Article Type: Article
• Acceptance Date: Jun 21, 2023
• Online Publication Date: Jul 14, 2023
• Deposit Date: Aug 7, 2023
• Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
• Print ISSN: 1569-1993
• Electronic ISSN: 1873-5010
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 23
• Issue: 1
• Pages: 80-86
• DOI: https://doi.org/10.1016/j.jcf.2023.06.008
• Keywords: Paediatric, Aztreonam, Pseudomonas aeruginosa, Cystic fibrosis, Eradication, Respiratory infections
• Public URL: https://keele-repository.worktribe.com/output/535920